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Background: Medication non-adherence is a complex health care problem. Due to non-adherence, substantial numbers
of cardiovascular patients benefit from their medication to only a limited extent. In order to improve adherence, a variety
of pharmacist-led interventions have been developed. However, even the most effective interventions achieved only a
modest positive effect. To be effective, interventions should be targeted at underlying barriers to adherence, developed
in a systematic manner and tailored to specific features of a target group and setting. The current paper describes the
design of the Cardiovascular medication non-Adherence Tailored Intervention (CATI) study aimed to evaluate the (cost-)
effectiveness of a patient-tailored intervention programme in patients using antihypertensive medication.
Methods: The CATI study is a randomised controlled trial that will be performed in 13 community pharmacies. Patients
aged 45–75 years using antihypertensive medication and considered non-adherent according to pharmacy dispensing
data, as well according to a self-report questionnaire, are eligible to participate. Patients in the intervention condition will
receive a patient-tailored, pharmacist-led intervention programme. This programme consists of a structured interview at
the pharmacy to identify patients’ barriers to adherence and to counsel patients in order to overcome these barriers.
The primary outcome is self-reported medication adherence measured with the MARS-5 questionnaire. Secondary
outcome measures are blood pressure, illness perceptions, quality of life and societal costs. A cost-effectiveness analysis
and process evaluation will also be performed.
Discussion: This study will provide insight into the (cost-)effectiveness of a patient-tailored, pharmacist-led intervention
programme in non-adherent patients using antihypertensive medication. This intervention programme allows community
pharmacists to support their patients in overcoming barriers to adherence and improving medication adherence in a
structured and patient-tailored manner. An effective intervention will not only enhance medication adherence,
but may also improve health outcomes and decrease health care utilisation and costs.
Trial registration: Netherlands Trial Register (identifier: NTR5017), registered on 2 February 2015.
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The World Health Organisation (WHO) provides
evidence-based guidelines for the treatment of a variety
of disorders, as specified in both pharmacological and
non-pharmacological treatment strategies [1]. These strat-
egies as implemented in numerous national guidelines
aim to reduce risks, (co)morbidity and mortality [1, 2].
Due to inadequately following pharmacological treatment
plans, i.e. medication non-adherence, a subgroup of pa-
tients benefits from their medication to only a limited ex-
tent. Medication non-adherence is a complex health care
problem and defined as the process by which patients take
their medication as agreed upon with their prescriber [3].
Causes of non-adherence are patient-, social/economic-,
condition-, treatment- or health care system-related [4, 5].
Pharmacological treatment of hypertension can result
in a reduced risk of cardiovascular events such as stroke
and myocardial infarction [5, 6]. Unfortunately, adher-
ence to antihypertensive medication is often suboptimal
and is associated with negative health outcomes, such as
cardiovascular events [7–9], higher risk of hospitalisation
[8–10] and increased health care costs [8]. A meta-
analysis of data of 376,162 patients from 20 studies
assessing adherence by using prescription refill data of
seven cardiovascular drug classes revealed an estimated
non-adherence rate of 43% [11]. Adherence varies de-
pending on drug class with non-adherence rates ranging
from 35% for angiotensin II-receptor blockers to 72% for
beta-blockers [12].
In order to improve patients’ adherence to medication,
a variety of mostly pharmacist-led interventions has
been developed. However, reviews summarising the re-
sults of a number of studies on the effectiveness of these
interventions revealed that in only half of the studies
adherence was significantly improved as compared to
usual care and that in only a few studies better treat-
ment outcomes were achieved [13–18]. One likely ex-
planation is that most studies did not use a theoretical
framework, crucial for understanding the complexities
of adherence behaviour. On top of that, most described
interventions did not made an effort to apply a patient-
tailored approach for identifying the specific causes or
barriers for individual patients [5, 19]. Finally, most
studies were targeted at the general population rather
than at patients non-adherent with their medication.
For this study, the Self-regulation Theory has been
chosen as a foundation of the intervention programme.
According to this theory patients seek to understand their
illness by developing a representation of the illness, its
cause, its effects, how long it will last and whether it can
be cured or controlled [20, 21]. These illness and treat-
ment representations guide their health behaviour. For in-
stance, if a patient regards his or her illness or risk factor
for an illness as a problem, the patient will perform health-related behaviour aimed to solve the problem, e.g. taking
medication [20, 22–25]. However, multiple factors influ-
ence adherence behaviour [5] and it should be recognised
that in this theory these influencing factors can be medi-
ated by patients’ illness and treatment representations.
The Cardiovascular medication non-Adherence Tai-
lored Intervention (CATI) study aims to evaluate the
(cost-)effectiveness of a patient-tailored, pharmacist-led
intervention (CATI intervention programme) aiming to
overcome barriers and improve antihypertensive medica-
tion adherence in comparison to usual care. The inter-
vention programme includes identifying factors that
influence patients’ adherence behaviour, discussing pa-
tient’s illness and treatment representations and suggest-
ing a plan to overcome barriers and improve medication
adherence.
Methods
The CATI study protocol was approved by the Medical
Ethics Committee of the VU University Medical Center,
Amsterdam (reference 2015/219). Written informed
consent will be obtained from all study participants.
Study design
A parallel-group randomised controlled trial will be per-
formed in 13 community pharmacies including 156 pa-
tients (Fig. 1). Patients will be randomly assigned to the
intervention or the control condition. Patients in the
intervention condition will receive the CATI intervention
programme performed by the pharmacist, in addition to
usual care (further described below in 'Control condition').
The effectiveness of the CATI intervention programme
will be measured during a 9-month follow-up. See
Additional file 1 for an overview of the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) 2013 checklist items [26]. See
Additional file 2 for the SPIRIT diagram of the trial
procedure.
Study population and setting
Patients will be recruited from community pharmacies
located in urban and rural areas in The Netherlands.
Participating pharmacies must have a subscription to the
Foundation for Pharmaceutical Statistics (SFK), which is
developed by the Royal Dutch Pharmacists Association.
SFK registers information on dispensing drugs and will
be used for the selection of eligible patients. Patients
aged 45–75 years using antihypertensive medication and
indicating to have hypertension by self-report are eligible
to participate. Antihypertensive medication includes
beta-blockers, calcium antagonists, diuretics, angiotensin
converting enzyme (ACE) inhibitors and angiotensin II-
receptor antagonists. Only patients non-adherent with
their antihypertensive medication according to pharmacy
Fig. 1 Design of the Cardiovascular medication non-Adherence Tailored Intervention (CATI) study
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tionnaire, are eligible. Exclusion criteria are the inability
to speak, read and write Dutch, and the use of special
medication-intake supporting services provided by the
pharmacy, i.e. repeat dispensing and pill packaging.
Inclusion procedure
To be included in the intervention or the control condi-
tion a two-step approach will be applied.
Step 1
Eligible patients will be identified by a SFK database
search which provides information on dispensed medica-
tion. For each class of antihypertensive medication SFK
calculates a score by dividing the number of covered
days by the length of the therapy window. The number
of covered days is calculated by summating the days in
the therapy window covered by usage periods which are
corrected for overlapping supplies. A score lower than
80% is considered non-adherent. SFK provides a list of
patients non-adherent in refilling at least one of theclasses of antihypertensive medication during the last
6 months. The researcher will check this list in order to
prevent selecting patients who are most likely falsely
identified as non-adherent due to switching drugs or
hospital stay.
Step 2
Patients identified as non-adherent in refilling antihyper-
tensive medication will be invited to fill out a question-
naire. This baseline questionnaire includes an Informed
Consent Form and the five-item Medication Adherence
Report Scale (MARS-5) questionnaire [27]. The MARS-
5 questionnaire assesses self-report medication intake
behaviour by five questions rated on a five-point scale
and ranges from 5 to 25 points. Patients with a score of
below 25 points are considered non-adherent.
Patients who are willing to participate and identified
as non-adherent with their antihypertensive medication
according to pharmacy dispensing data, as well accord-
ing to the self-report questionnaire, will be included in
the study. Patients identified as non-adherent with only
van der Laan et al. Trials  (2017) 18:29 Page 4 of 9one non-adherence measure will not be included. Pa-
tients not willing to participate will be asked to fill out a
short questionnaire assessing demographic variables and
reasons for their nonparticipation.
Randomisation
To each eligible patient an unique serial number will be
assigned. Subsequently, a member of the research team
will perform the randomisation process using blocking
[28] with a block size of 4, a random cell selection a 1:1
allocation ratio. A list of patients randomised to the
intervention or the control condition will be handed to
the pharmacist and pharmacy technician, respectively.
Blinding of the participants, pharmacists and pharmacy
technicians to treatment allocation is not possible due to
the nature of the intervention.
Intervention condition
Patients in the intervention condition will receive the
CATI intervention programme in addition to usual care.
The programme is a patient-tailored, pharmacist-led,
theory-based intervention programme to enhance
adherence with the use of antihypertensive medication.
It consists of two steps. First, the patients’ barriers to
adherence will be identified, and second, tailored infor-
mation and advice on the identified barriers and specific
needs of the patient will be provided. The Self-
regulation Theory suggests that patients make an illness
and treatment representation which guides their health
behaviour. By providing tailored information to the pa-
tient regarding the potential risks of high blood pressure
and the need for treatment, it is expected to increase pa-
tients’ understanding and perceived need to be adherent
with their antihypertensive medication. The programme
will be executed by the pharmacist and includes two
visits to the pharmacy.
First consult
The pharmacist invites the patient for a consult in the
pharmacy. The consult starts by interviewing the patient
using a semistructured interview guide, called the Quick
Barrier Scan (QBS). The aim of the QBS is to explore
patients’ barriers to adherence to medication assessed by
means of 12 questions, for instance concerning know-
ledge, side effects, forgetfulness, difficulties with medica-
tion intake and lack of motivation. Patients will also be
asked about their own ideas of intake barriers. Based
upon the identified barrier(s) an intervention module
will be selected according to the Tailored Intervention
Guide (TIG). The TIG provides an overview of five
intervention modules aiming to overcome different bar-
riers to adherence. Each assessed barrier in the QBS
conforms to an intervention module in the TIG. If no
clear barrier can be identified with the QBS, the firstintervention module will be conducted. The five inter-
vention modules include: (1) Providing Information, (2)
Providing Tools, (3) Dealing with Side Effects, (4) Over-
coming Practical Problems and (5) Diminishing Negative
Beliefs. Each intervention module consists of three com-
ponents. During the first component, the patient will be
provided with information regarding the representation
and potential risks of high blood pressure, the use of an-
tihypertensive medication and living a healthy lifestyle.
During the second component, the pharmacist will give
the patient tailored advice on overcoming the identified
barriers. The content of the second component is differ-
ent for each intervention module. For instance, possible
recommendations of the second intervention module
(Providing Tools) are connecting intake with daily recur-
ring activities or the use of a pill box or medication re-
minder alarm. Recommendations of the third intervention
module (Dealing with Side Effects) are to balance patients’
advantages and disadvantages of medication use; whereas
examples of recommendations of the fourth intervention
module (Practical Problems) are to register a patient for
an intake-supporting service, i.e. pill packaging. During
the third component, a summary is made from the infor-
mation and advice discussed by the pharmacist in order to
provide the patient with a short overview of the first con-
sult. This overview can be used as an action plan. The
intervention programme and materials are partly based
upon the promising results of a previous study in which
the feasibility of a modular intervention programme in pa-
tients with diabetes was evaluated [29]. On top of that, the
intervention materials (the QBS and the TIG) were further
developed based upon our own research including a sys-
tematic literature review and a cross-sectional study (man-
uscripts in preparation). The systematic review aimed to
provide an overview of the factors influencing antihyper-
tensive medication adherence. The cross-sectional study
used a questionnaire to assess barriers to adherence in a
Dutch population using cardiovascular medication. These
results provided a complete overview of potential barriers
to medication adherence which should be incorporated in
the intervention materials. Lastly, the intervention mate-
rials were approved by an expert panel including a
pharmacist, a general practitioner and a sociologist.
Follow-up consult
Approximately 3 months after the first consult a follow-
up consult will be planned with the patient. The purpose
of this follow-up consult is to discuss patients’ implemen-
tation of and patients’ experiences with the action plan. If
needed, the developed action plan of the first consult will
be adjusted based upon patients’ experiences.
During the first consult, the follow-up consult and
during an additionally planned visit to the pharmacy, pa-
tients’ systolic and diastolic blood pressure will be
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cording to a protocol.
Training
Participating pharmacists will follow a 1-day training
session. The training session comprises a theoretical and
a practical part. During the theoretical part, background
information on medication non-adherence will be dis-
cussed and instructions will be given on study design,
protocol and intervention materials. An experienced
communication lecturer will provide information and in-
structions on how to communicate with patients. During
the practical part, the pharmacists will practise with
communication skills and intervention materials in a
patient-pharmacist role-playing setting. Before and after
the training session the pharmacists will fill out a form
to assess the potential improvement of their knowledge
and competencies.
Control condition
Patients in the control condition will receive usual care ac-
cording to the Dutch guidelines of the Royal Dutch Phar-
macists Association [30]. In summary, the care according
to these guidelines consist of checking and dispensing of
prescribed drugs, providing instructions on medication
use, and providing information about intended effects and
possible side effects, during first and second dispensing.
Primary outcome measure
Self-reported medication adherence will be assessed with
the MARS-5 questionnaire at baseline and after 3, 6 and
9 months [27]. The MARS-5 questionnaire comprises
five statements of adherence-related behaviour rated on
a five-point scale, where 1 = ‘always’, 2 = ‘often’, 3 = ‘some-
times’, 4 = ‘rarely’ and 5 = ‘never’. Scores for each item
will be summated to give a total score, ranging from 5 to
25 points. A score below 25 points is considered non-
adherent. The questionnaire distinguishes intentional
non-adherence and unintentional non-adherence. The
statements assessing intentional non-adherence are ‘I alter
the dose of my medicines’, ‘I stop taking my medicines for
a while’, I decide to miss out on a dose of my medicines’
and ‘I take less of my medicines than instructed’. The
statement assessing unintentional non-adherence is ‘I for-
get to take my medicines’. The MARS-5 questionnaire is
easy to use and shows to be a valid and reliable tool for
measuring patients’ non-adherence to medication across
different illnesses including asthma, diabetes and hyper-
tension [27, 31–33]. The internal reliability (Cronbach’s α)
ranged from 0.67 to 0.90; test-retest reliability (Pearson’s
r) was 0.97; and concurrent validity (Pearson’s r) with the
Morisky Medication Adherence Scale [34] was 0.62. The
MARS-5 questionnaire was selected because it is a
sufficiently-validated and easy-to-use tool. Furthermore,in addition to measuring the extent of non-adherence, it
can distinguish between patients with intentional and un-
intentional medication non-adherence.
Secondary outcome measures
Secondary outcomes include patients’ attitudes and beliefs
towards medication, quality of life (QoL), illness percep-
tions, costs and systolic and diastolic blood pressure.
Attitudes and beliefs towards medication
Patients’ attitudes and beliefs towards medication will be
assessed with the specific Beliefs about Medicines Ques-
tionnaire (BMQ) [35, 36] at baseline and after 3, 6 and
9 months. The BMQ Specific can be subdivided into the
BMQ Specific Necessity and the BMQ Specific Concern.
The BMQ Specific Necessity measures the patients’ be-
liefs of the necessity of taking the medication and the
BMQ Specific Concern measures the patients’ concerns
about taking medication. Both subscales range from 5 to
25. The BMQ Necessity-Concern differential can be
calculated as the difference between the Concern and
Necessity subscales. The BMQ specific subscales can be
used to categorise patients into four attitudinal groups:
accepting (high necessity, low concerns), ambivalent
(high necessity, high concerns), indifferent (low neces-
sity, low concerns) and sceptical (low necessity, high
concerns). Research shows evidence on good reliability
and acceptable validity of the BMQ scales and supports
its use as a research tool when investigating patients’ be-
liefs about medication [35–37]. The internal reliability
(Cronbach’s α) for both the Concern and Necessity sub-
scales was 0.83. When assessing the validity of the BMQ
with the MARS-5, significant predictive correlations
were found for both the Concern and Necessity sub-
scales [37]. The measurement of patient’s beliefs about
medication is important because it provides insight into
the mechanism by which medication beliefs might influ-
ence medication adherence.
Quality of life
Patients’ QoL will be assessed using both the valid and
reliable 12-Item Short Form (SF-12) questionnaire [38]
and the valid and reliable EuroQol (EQ-5D-5L) ques-
tionnaire [39, 40] at baseline and after 3, 6 and 9 months.
The SF-12 questionnaire consists of 12 questions cover-
ing eight dimensions of health, i.e. general health per-
ception, physical functioning, limitations due to physical
health problems, bodily pain, vitality, social functioning,
emotional functioning and general mental health. The
eight domains can produce two summary scores for
physical health and mental health. The EQ-5D-5L ques-
tionnaire is a standardised instrument measuring five
health dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression) with five
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health states will be converted into utility scores using
the Dutch tariff [41]. Utility scores reflect the desirability
of a health state and are anchored at 0 (‘death’) and 1
(‘perfect health’). Quality-adjusted life years will be
calculated by multiplying the utility of a particular health
state by the time spent in that health state using the
area-under-the-curve method. Transitions between health
states are considered linear.
Illness perceptions
The Brief Illness Perceptions Questionnaire (Brief IPQ)
is a nine-item scale designed to assess patients’ cognitive
and emotional representations of illness [42]. All items
except the causal question are rated on 0 to 10 scale.
Five items assess cognitive illness representations: conse-
quences, timeline, personal control, treatment control
and identity. Two items assess emotional representa-
tions: concerns and emotions. One item assesses illness
comprehensibility. The causal representation question
asks listing the three most important causal factors of
illness. The reliable and valid Brief IPQ is measured at
baseline and after 3, 6 and 9 months.
Costs
Costs will be measured from a societal perspective using
adapted versions of the iMTA Medical Cost Question-
naire (iMCQ) [43] and the iMTA Productivity Cost
Questionnaire (iPCQ) [44] including costs of health care
utilisation, informal care, and work absenteeism and
presenteeism. Medication use will be retrieved from the
patient’s pharmacy. If available, Dutch guideline prices
will be used to value resource use. Medication use will
be valued using prices set by the Royal Dutch Pharma-
cists Association. Lost productivity costs will be calcu-
lated according to the friction cost approach using
Dutch mean incomes [45]. According to the friction cost
approach a sick employee is replaced after a certain
amount of time (the friction period) after which there
are no further lost productivity costs [46]. All costs will
be adjusted to the year in which most data is collected
using consumer price indices.
Blood pressure
Systolic and diastolic blood pressure is a clinical second-
ary outcome and will be measured with an automatic
sphygmomanometer in both the intervention and the
control conditions according to a standardised protocol.
In the intervention condition blood pressure will be
measured by the pharmacists at the start of the first con-
sult, at the start of the follow-up consult and at a final
pharmacy visit. In the control condition blood pressure
will be measured by the pharmacy technician during
three pharmacy visits at baseline and after 3 and6 months. At each visit blood pressure will be measured
three times, each 2 min apart, in a seated position.
Pilot study
Based on the results of a pilot study the CATI interven-
tion programme was improved and finalised. Ten pa-
tients from three community pharmacies participated in
the pilot study. These participants filled out the baseline
questionnaire and visited the pharmacy for the first con-
sult. Logistics, questionnaires, use of study protocol and
intervention materials, and the feasibility of the inter-
vention programme were evaluated. After the pilot study
some aspects of the intervention programme were chan-
ged, for instance putting more emphasis on the follow-
up consult and development of an action plan; simplify-
ing the structure and use of the intervention materials;
and adapting logistic aspects to increase feasibility.
Statistical analyses
Descriptive statistics will be used to characterise the study
population. Dropout and loss to follow-up will also be de-
scribed. The effect analyses will be performed according
to the ‘intention-to-treat’ and ‘per-protocol’ principles.
Linear and logistic mixed-model analyses will be used to
assess the effect of the intervention programme by com-
paring the differences between the intervention and the
control conditions. Mixed-model analysis is needed in
order to take into account clustering on pharmacy level
and repeated measurements in one patient. Adjustments
will be made for possible confounders such as gender, age
and education level. The researcher will be blinded during
data analyses.
Sample size
A sample size calculation for proportions has been per-
formed. The sample size is based upon the difference in
percentage of adherent participants over 9 months of
follow-up between the intervention and the control condi-
tions. A difference of 20% is considered relevant. At base-
line, all participants are non-adherent as measured with
the self-report adherence questionnaire. The expected
percentage of adherent participants (MARS-5 = 25) at the
end of the study is 30% for the intervention condition and
10% for the control condition. When using an alpha of
0.05 and a beta of 0.20, a group size of 60 is sufficient, tak-
ing the clustered and longitudinal design into account. To
adjust for a loss to follow-up of approximately 30%, we
will include 156 patients.
Process evaluation
The process evaluation assesses the extent to which the
CATI intervention programme is performed according
to study protocol and gives insight into barriers and fa-
cilitators in executing the different components of the
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that is spent by the pharmacists in executing the inter-
vention programme and the intervention modules that
are selected and performed. Data on these topics will be
collected using an administration form. In addition,
semistructured interviews will be held with the partici-
pating pharmacists at the end of the study in order to
record experiences and opinions on the intervention
programme. The presence of possible contamination will
also be assessed by interviewing the pharmacy tech-
nicians. Furthermore, after the follow-up consult partici-
pants will fill out a questionnaire to evaluate the
different components of the intervention programme.
Economic evaluation
Both a cost-effectiveness analysis and a cost-utility ana-
lysis will be performed according to the intention-to-
treat principle. Missing cost and effect data will be im-
puted using Multiple Imputation by Chained Equations
(MICE) [47]. To account for the skewed distribution of
costs Predictive Mean Matching will be used in the
MICE procedure. The number of imputed datasets will
be increased until the loss of efficiency is less than 5%
[48]. The results of the imputed datasets will be pooled
according to Rubin’s rules. Bivariate regression analyses
will be used to estimate cost and effect differences while
adjusting for potential confounders and maintaining the
correlation between costs and effects. Incremental Cost-
Effectiveness Ratios (ICERs) will be calculated by divid-
ing the mean difference in total societal costs by the
mean difference in effects. Bias-corrected and acceler-
ated bootstrapping with 5000 replications will be used to
estimate 95% confidence intervals around cost and effect
differences, and to estimate the uncertainty surrounding
the ICERs which will be graphically presented on a cost-
effectiveness plane [49]. Cost-effectiveness acceptability
curves will be estimated in which the probability that
the intervention programme is cost-effective in compari-
son to usual care is plotted on the y-axis, while the
willingness-to-pay per incremental unit of effect is plot-
ted on the x-axis [50].
Discussion
This study is expected to add evidence to the (cost-)effect-
iveness of a patient-tailored, theory-driven, pharmacist-led
intervention programme as compared to usual care in pa-
tients using antihypertensive medication. The intervention
programme includes a variety of tools to support patients
to overcome barriers to adherence, thereby improving
medication adherence. It is expected that patients will be
encouraged to adjust their adherence behaviour. This will
be achieved by learning from the provided information,
following the pharmacists’ advice and by using supporting
aids. In addition, performing an action plan and discussingthe use and results of the plan at a follow-up visit may in-
crease these achievements. Moreover, the personal atten-
tion of the pharmacist towards the patient is expected to
be a stimulating factor for behavioral change.
A strength of this study is the theory-driven and
patient-tailored approach of the intervention programme.
All patients have their own medication intake behaviour,
experience their own problems and barriers to adherence
and have their own needs. By focussing on identifying pa-
tients’ barriers in the initial phase and subsequently ad-
dressing these barriers by providing specific information
and advice to patients, the patient-tailored approach is
applied. Moreover, encouraging patients to self-regulate
their medication intake behaviour by overcoming specific
barriers will lead to the improvement of medication ad-
herence. In addition, this intervention programme has
been developed for patients non-adherent with their anti-
hypertensive medication, and will not unnecessarily be
addressed to the general population of antihypertensive
medication users. Another strength of the study is the
execution of a pilot study which resulted in improving
and finalising the intervention programme. The study
will be conducted in daily clinical practice. This in-
creases the feasibility of implementing the CATI inter-
vention programme in a community pharmacy setting
on a large scale. Furthermore, alongside the study a
process evaluation will be performed. This will enable
us to assess the implementation fidelity and add to a
careful interpretation of the results of the study.
The MARS-5 questionnaire has been selected as the
primary outcome for this study. Two studies showed
poor sensitivity results of the MARS-5 questionnaire
[51, 52]. This could be a limitation of this study. An ex-
planation for these results could be the use of the Medi-
cation Possession Ratio as a reference standard. This
method calculates the extent to which patients refill
their medication, rather than calculating the extent to
which patients take their medication. Despite these re-
sults, the MARS-5 questionnaire has several advantages.
First, the questionnaire performs well on other psychomet-
ric properties. Second, the response scale allows patients
to be graded in terms of the frequency with which they en-
gage in non-adherent behaviours. Third, the questionnaire
can distinguish between patients with intentional and
unintentional medication non-adherence. Lastly, this ques-
tionnaire is relatively short and easy to use. Another limi-
tation of this study is that, due to the nature of the
intervention, it is not possible to blind the researcher,
patients, pharmacists or pharmacy technicians to the
group allocation of participants. To minimise possible as-
certainment bias before data collection participants were
informed about being randomised into one out of two pro-
grammes, with either three blood pressure measurements
or two consults and three blood pressure measurements.
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data collection, the researcher will be blinded during data
analyses. A final limitation of this study is that due to per-
forming the randomisation at the individual level both the
intervention and the control conditions will be conducted
in one pharmacy which can lead to contamination. To
minimise contamination within one pharmacy, the inter-
vention programme and blood pressure measurements
will be performed by a pharmacist, whereas the blood
pressure measurements in the control condition will be
performed by a pharmacy technician; previously, phar-
macy technicians had been instructed to perform no activ-
ities other than usual care during the three blood pressure
measurement visits.
If the CATI intervention programme is feasible and ef-
fective, it could potentially be extrapolated to other groups
of patients in whom medication non-adherence is also a
problem. The information gained from this study may
prove useful for policy-makers, health care providers, and
researchers who are in the process of improving adher-
ence with the use of (cardiovascular) medication.
Trial status
The inclusion of patients and the collection of data started
in March 2016. The inclusion of patients ended in the
third quarter of 2016. Results will be expected in 2017.
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